Clinical Research Directory
Browse clinical research sites, groups, and studies.
Inhaled Hydrogen Therapy's Effect on Early Recurrences of Atrial Fibrillation Post-ablation.
Sponsor: University Hospital, Grenoble
Summary
The goal of this clinical trial is to testing the perioperative inhaled hydrogen (H2) administration's effects during atrial fibrillation ablations (AF) to reduce both early and late recurrences associated with this procedure. Researchers will compare H2 inhalation to the standard of care to see if we observe a reduction in AF recurrence after ablation but also a reduction in rehospitalizations or emergency visits for cardioversion, and consequently an improvement in quality of life. Participants will: * have an AF ablation associated to an hydrogen therapy or standard of care * complete quality of life questionnaires * record ECG on KardiaMobile© * Keep a diary of their symptoms * have a blood test * have 2 follow-up visits (after 3 and 12 months) and 2 phone calls (after 6 and 9 months)
Official title: Inhaled Hydrogen Therapy's Effect on Early Recurrences of Atrial Fibrillation Post-ablation. Phase II, Multicenter, Randomized, Controlled, Open-label Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
124
Start Date
2027-01
Completion Date
2029-09
Last Updated
2026-11-10
Healthy Volunteers
No
Conditions
Interventions
Hydrogen Gas (H2)
Patients treated with inhaled hydrogen therapy in the perioperative period (initiation of inhaled hydrogen therapy from hospital admission until discharge, except in the operating room) (dosage : H2/N2 3.6%/96.4%, 1 L/min 24 hours a day)
Locations (2)
Chu Grenoble Alpes
Grenoble, Isère, France
Hopital Louis Pradel
Bron, Rhone, France